The latest developments across the GLP-1 landscape, from new drug approvals and clinical research to pricing changes and policy shifts. Stay informed on the updates that affect Ozempic, Wegovy, Mounjaro, and the wider category.
News & Updates
Researchers are developing implantable devices that could one day deliver GLP-1-like effects without weekly injections. Here's what the science shows so far, how this compares to current options like semaglutide and tirzepatide, and what patients should know before getting excited.
"Ozempic feet" is a colloquial term for foot-related changes some people experience while losing weight rapidly on GLP-1 medications like semaglutide. This guide explains what causes it, what symptoms to watch for, and practical steps you can take to protect your foot health during treatment.
Some people with bulimia and other eating disorders report that GLP-1 medications significantly reduced their urges to binge eat. But this emerging area comes with real risks, important caveats, and questions that researchers are still working to answer. Here is what patients and caregivers need to know right now.
A small implantable device that delivers GLP-1 medication continuously is moving through development as a potential solution for long-term weight maintenance. Here is what patients currently on injections or considering GLP-1 therapy need to know about this emerging technology and how it compares to existing options.
Eli Lilly's oral GLP-1 medication Foundayo launched to quieter-than-expected demand, raising questions for patients weighing oral versus injectable options. Here's what the slow start actually means for your treatment choices, costs, and access in 2025 and beyond. We break it down without the hype.
High fashion is pushing back against the slimmer silhouettes associated with GLP-1 medications like Ozempic and Wegovy. This cultural moment raises real questions for people on these medications about body image, stigma, and staying grounded in their health goals. Here's how to tune out the noise and focus on what actually matters.
Research is finding a surprising connection between GLP-1 medications like Ozempic and Wegovy and reduced use of alcohol, tobacco, and other risky substances. The same brain pathways that drive overeating may also drive addictive behaviors, and GLP-1 drugs appear to influence both. Here's what patients should know.
Bank of America is warning that patient dropout from Wegovy could put pressure on Hims & Hers financials. For people using or considering GLP-1 medications through telehealth platforms, this raises real questions about provider stability, medication access, and long-term costs. Here's what you need to know before choosing a platform.
